IntegraGen SA (ALINT.PA)
EUR 0.54
(9.09%)
EUR 0.54
(9.09%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.01 Million EUR | -9.8% |
| 2022 | -6355.00 EUR | -114.54% |
| 2021 | 43.69 Thousand EUR | 148.85% |
| 2020 | -89.45 Thousand EUR | -101.56% |
| 2019 | 5.71 Million EUR | 138.43% |
| 2018 | 2.39 Million EUR | 89.99% |
| 2017 | 1.26 Million EUR | -12.17% |
| 2016 | 1.43 Million EUR | 32.97% |
| 2015 | 1.08 Million EUR | -10.53% |
| 2014 | 1.2 Million EUR | 959.26% |
| 2013 | -140.53 Thousand EUR | -217.06% |
| 2012 | 120.05 Thousand EUR | 271.31% |
| 2011 | -70.08 Thousand EUR | -105.4% |
| 2010 | 1.29 Million EUR | 241.9% |
| 2009 | -914.46 Thousand EUR | 34.0% |
| 2008 | -1.38 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -679 Thousand EUR | 0.0% |
| 2023 Q2 | -357.73 Thousand EUR | 0.0% |
| 2023 FY | -6978.00 EUR | -9.8% |
| 2023 Q4 | 2.69 Million EUR | 0.0% |
| 2022 Q4 | 110.85 Thousand EUR | 0.0% |
| 2022 FY | -6355.00 EUR | -114.54% |
| 2022 Q2 | -117.2 Thousand EUR | 0.0% |
| 2021 Q2 | -572 Thousand EUR | 0.0% |
| 2021 FY | 43.69 Thousand EUR | 148.85% |
| 2021 Q4 | 3.32 Million EUR | 0.0% |
| 2020 Q2 | 343.88 Thousand EUR | 0.0% |
| 2020 FY | -89.45 Thousand EUR | -101.56% |
| 2020 Q4 | -433.33 Thousand EUR | 0.0% |
| 2019 Q2 | 1.58 Million EUR | 0.0% |
| 2019 FY | 5.71 Million EUR | 138.43% |
| 2019 Q4 | 295.72 Thousand EUR | 0.0% |
| 2018 Q2 | 1.16 Million EUR | 0.0% |
| 2018 Q4 | 1.22 Million EUR | 0.0% |
| 2018 FY | 2.39 Million EUR | 89.99% |
| 2017 Q2 | 379.05 Thousand EUR | 0.0% |
| 2017 FY | 1.26 Million EUR | -12.17% |
| 2017 Q4 | 882.76 Thousand EUR | 0.0% |
| 2016 Q4 | 1.19 Million EUR | 0.0% |
| 2016 Q2 | 552.87 Thousand EUR | 0.0% |
| 2016 FY | 1.43 Million EUR | 32.97% |
| 2015 FY | 1.08 Million EUR | -10.53% |
| 2015 Q4 | 801.43 Thousand EUR | 0.0% |
| 2015 Q2 | 279.01 Thousand EUR | 0.0% |
| 2014 Q4 | 705.68 Thousand EUR | 0.0% |
| 2014 FY | 1.2 Million EUR | 959.26% |
| 2014 Q2 | 501.89 Thousand EUR | 0.0% |
| 2013 Q2 | -220.93 Thousand EUR | 0.0% |
| 2013 Q4 | 80.39 Thousand EUR | 0.0% |
| 2013 FY | -140.53 Thousand EUR | -217.06% |
| 2012 Q4 | -36.42 Thousand EUR | -221.37% |
| 2012 Q3 | 30.01 Thousand EUR | 0.0% |
| 2012 FY | 120.05 Thousand EUR | 271.31% |
| 2012 Q1 | 30.01 Thousand EUR | 0.0% |
| 2012 Q2 | 30.01 Thousand EUR | 0.0% |
| 2011 Q3 | -17.52 Thousand EUR | 0.0% |
| 2011 Q1 | -17.52 Thousand EUR | 0.0% |
| 2011 Q2 | -17.52 Thousand EUR | 0.0% |
| 2011 Q4 | 30.01 Thousand EUR | 271.31% |
| 2011 FY | -70.08 Thousand EUR | -105.4% |
| 2010 Q4 | -17.52 Thousand EUR | -105.4% |
| 2010 Q3 | 324.4 Thousand EUR | -0.0% |
| 2010 Q1 | 324.4 Thousand EUR | -0.0% |
| 2010 Q2 | 324.41 Thousand EUR | 0.0% |
| 2010 FY | 1.29 Million EUR | 241.9% |
| 2009 FY | -914.46 Thousand EUR | 34.0% |
| 2009 Q1 | -228.61 Thousand EUR | -0.0% |
| 2009 Q2 | -228.61 Thousand EUR | 0.0% |
| 2009 Q3 | -228.61 Thousand EUR | -0.0% |
| 2009 Q4 | 324.41 Thousand EUR | 241.9% |
| 2008 Q1 | -346.36 Thousand EUR | 0.0% |
| 2008 Q2 | -346.36 Thousand EUR | 0.0% |
| 2008 Q3 | -346.36 Thousand EUR | 0.0% |
| 2008 FY | -1.38 Million EUR | 0.0% |
| 2008 Q4 | -228.61 Thousand EUR | 34.0% |
| 2007 Q4 | -346.36 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -712.019% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -28.214% |
| Adocia SA | 1.38 Million EUR | -262.331% |
| Aelis Farma SA | 12.35 Million EUR | 59.392% |
| Biophytis S.A. | -803 Thousand EUR | 724.941% |
| Advicenne S.A. | 1.42 Million EUR | -251.913% |
| genOway Société anonyme | 20.1 Million EUR | 75.034% |
| Medesis Pharma S.A. | -2.66 Million EUR | 288.32% |
| Neovacs S.A. | 29.31 Thousand EUR | -17019.056% |
| NFL Biosciences SA | -56.06 Thousand EUR | 9050.985% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -133.092% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 453.577% |
| Sensorion SA | 3.78 Million EUR | -32.483% |
| Theranexus Société Anonyme | -4.63 Million EUR | 208.183% |
| TME Pharma N.V. | -127 Thousand EUR | 4051.402% |
| Valbiotis SA | 2.66 Million EUR | -88.091% |
| TheraVet SA | -530.79 Thousand EUR | 1045.425% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -296.076% |
| DBV Technologies S.A. | 4.15 Million EUR | -20.644% |
| Genfit S.A. | 28.22 Million EUR | 82.22% |
| GeNeuro SA | -293.8 Thousand EUR | 1808.06% |
| Innate Pharma S.A. | -4.12 Million EUR | 221.773% |
| Inventiva S.A. | 17.5 Million EUR | 71.324% |
| MaaT Pharma SA | 1.65 Million EUR | -203.219% |
| MedinCell S.A. | 9.28 Million EUR | 45.97% |
| Nanobiotix S.A. | 36.2 Million EUR | 86.14% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -125.338% |
| Poxel S.A. | 1000.00 EUR | -501728.0% |
| GenSight Biologics S.A. | 3 Million EUR | -67.276% |
| Transgene SA | -28.4 Million EUR | 117.668% |
| Valneva SE | 52.83 Million EUR | 90.502% |